Mitcham Industries Inc. (MIND) Drops 13.97% on January 20

Equities Staff |

Mitcham Industries Inc. (MIND) was one of the Russell 2000's biggest losers for Wednesday January 20 as the stock slid 13.97% to $2.34, a loss of $-0.38 per share. Starting at an opening price of $2.68 a share, the stock traded between $2.24 and $2.68 over the course of the trading day. Volume was 26,662 shares over 177 trades, against an average daily volume of 29,435 shares and a total float of 12.09 million.

The losses send Mitcham Industries Inc. down to a market cap of $28.29 million. In the last year, Mitcham Industries Inc. has traded between $7.92 and $2.67, and its 50-day SMA is currently $3.54 and 200-day SMA is $4.14.

Mitcham Industries Inc leases and sells geophysical and other equipment used primarily by seismic data acquisition contractors to perform seismic data acquisition surveys on land, in transition zones and deep water marine areas.

Mitcham Industries Inc. is based out of Huntsville, TX and has some 187 employees. Its CEO is Guy Malden / Robert P. Capps.

For a complete fundamental analysis analysis of Mitcham Industries Inc., check out’s Stock Valuation Analysis report for MIND. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


A peer-to-Peer authentic photo marketplace disrupting the $10B commercial photography industry.


Pinterest is a visual discovery and planning tool. Users ("Pinners") use the site and apps to get ideas for their future, such as recipes, places to travel, and products to…